AARD
Aardvark Therapeutics, Inc.Company Information
- Company Name
- Aardvark Therapeutics, Inc.
- CIK
- CIK0001774857
- Category
- <br>Emerging growth company
- Ticker: Exchange
- AARD: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- AARD
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-12-11
- Last sale
- 2026-09-11
- Shares purchased (TTM)
- 25,000
- Shares sold (TTM)
- 62,000
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 9,432,329
- Shares outstanding
- 21,846,251
- Ownership
- 43.18%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- -25.17%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||
| Cash And Cash Equivalents At Carrying Value | 74 | 62 | 47 | 39 | 26 | 27 | ||||||
| Short Term Investments | 0 | 29 | 63 | 87 | 116 | 125 | ||||||
| Prepaid Expense And Other Assets Current | 7 | 2 | 2 | 3 | 3 | 3 | ||||||
| Assets Current | 81 | 94 | 112 | 129 | 145 | 155 | ||||||
| Operating Lease Right Of Use Asset | 1 | 0 | 0 | 0 | 1 | 1 | ||||||
| Other Assets Noncurrent | 0 | 5 | 5 | 4 | 2 | 2 | ||||||
| Assets | 81 | 99 | 117 | 133 | 147 | 157 | ||||||
Liabilities | ||||||||||||
| Accounts Payable Current | 2 | 4 | 2 | 4 | 5 | 3 | ||||||
| Accrued Liabilities Current | 4 | 7 | 8 | 6 | 5 | 3 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 6 | 12 | 11 | 11 | 10 | 6 | ||||||
| Operating Lease Liability Noncurrent | 0 | - | 0 | 0 | 0 | 0 | ||||||
| Other Liabilities Noncurrent | - | - | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 7 | 12 | 11 | 11 | 11 | 6 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 227 | 224 | 222 | 221 | 219 | 218 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 0 | 0 | -0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -152 | -138 | -116 | -98 | -82 | -68 | ||||||
| Stockholders Equity | 75 | 87 | 107 | 122 | 137 | 151 | ||||||
| Liabilities And Stockholders Equity | 81 | 99 | 117 | 133 | 147 | 157 | ||||||
| Temporary Equity Par Or Stated Value Per Share | - | - | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Temporary Equity Shares Authorized | - | - | 0 | 0 | 0 | 0 | ||||||
| Temporary Equity Shares Issued | - | - | 0 | 0 | 0 | 0 | ||||||
| Temporary Equity Shares Outstanding | - | - | 0 | 0 | 0 | 0 | ||||||
| Temporary Equity Liquidation Preference | - | - | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 490 | 490 | 490 | 490 | 490 | 490 | ||||||
| Common Stock Shares Issued | 22 | 22 | 22 | 22 | 22 | 22 | ||||||
| Shares Outstanding | 22 | 22 | 22 | 22 | 22 | 22 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAardvark Therapeutics, Inc. (AARD) — SEC Financial Statements & Analysis
Aardvark Therapeutics, Inc. (AARD) is a pharmaceutical preparations company, incorporated in DE. Aardvark Therapeutics, Inc. trades on Nasdaq as: AARD. Aardvark Therapeutics, Inc. (AARD)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Aardvark Therapeutics, Inc. carries a market cap of $125.83M, a P/E ratio of -1.80x, a P/B ratio of 1.68x, a P/S ratio of 30.99x, an enterprise value of $51.99M, and an EV/EBITDA multiple of -0.70x. On profitability, it posts an operating margin of -1821.55%, a net margin of -1721.40%, a Return on Equity (ROE) of -66.02%, a Return on Assets (ROA) of -61.06%, and a Return on Invested Capital (ROIC) of -132.11%. Per share, it reports EPS of $-3.20, diluted EPS of $-3.20, free cash flow per share of $-3.18, and a dividend per share of $0.00. On the balance sheet, it maintains a current ratio of 12.63x, a quick ratio of 11.57x, working capital of $74.27M, a debt-to-equity ratio of 0.09x, a debt ratio of 0.08, free cash flow of $-69.41M (TTM), and net debt of $-73.85M. Figures sourced from SEC EDGAR.
- Market Cap
- $125.83M
- P/E TTM
- -1.80x
- EPS TTM
- $-3.20
- P/B TTM
- 1.68x
- ROE TTM
- -66.02%
- ROA TTM
- -61.06%
- Debt To Equity
- 0.09x
- Free Cash Flow TTM
- $-69.41M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Aardvark Therapeutics, Inc. in?
Aardvark Therapeutics, Inc. (AARD) operates in the Pharmaceutical Preparations industry.
What exchange does AARD trade on?
Aardvark Therapeutics, Inc. (AARD) trades on the Nasdaq.
Where is Aardvark Therapeutics, Inc. incorporated?
Aardvark Therapeutics, Inc. is incorporated in DE.
When was Aardvark Therapeutics, Inc. (AARD)'s most recent SEC filing?
Aardvark Therapeutics, Inc. (AARD)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is AARD's market cap?
Aardvark Therapeutics, Inc. (AARD) has a market capitalization of $125.83M as of 2026-06-30.
What is AARD's EPS (earnings per share)?
Aardvark Therapeutics, Inc. (AARD)'s trailing twelve month EPS is $-3.20 as of 2026-06-30.
What is AARD's ROE (return on equity)?
Aardvark Therapeutics, Inc. (AARD)'s trailing twelve month Return on Equity (ROE) is -66.02% as of 2026-06-30.
What is AARD's ROA (return on assets)?
Aardvark Therapeutics, Inc. (AARD)'s trailing twelve month Return on Assets (ROA) is -61.06% as of 2026-06-30.
What is AARD's ROIC (return on invested capital)?
Aardvark Therapeutics, Inc. (AARD)'s trailing twelve month Return on Invested Capital (ROIC) is -132.11% as of 2026-06-30.
What is AARD's EV/EBITDA?
Aardvark Therapeutics, Inc. (AARD)'s trailing twelve month EV/EBITDA is -0.70x as of 2026-06-30.